Industry & Policy News

[UCB] RYSTIGGO® injection for subcutaneous infusion is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor, resulting in the reduction of circulating IgG.1,4. It is the only FDA-approved treatment in adults for both anti-acetylcholine receptor andanti-muscle-specific tyrosine kinase antibody-positive generalized myasthenia gravis.

[Biora Therapeutics, Inc.] Biora Therapeutics, Inc. announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development. The patents are directed to methods of treating ulcerative colitis using an ingestible device that delivers one or more therapeutic agents to the proximal part of the large intestine.

[Susan G. Komen] Susan G. Komen® announced the awarding of 49 new grants to researchers at 28 leading institutions in the US. The $19.3 million in new grants support Komen’s mission to end breast cancer.

[BioNTech SE] BioNTech SE announced that the first patient with NSCLC has been treated in a pivotal Phase III trial evaluating the companies’ next-generation anti-CTLA-4 antibody candidate BNT316/ONC-392.

[The Hippocratic Post] Dr. Robert Wynn, Consultant Paediatric Haematologist at the Manchester Children’s Hospital, has won Clinical Supporter of the Year at the Anthony Nolan Supporter Awards 2023 for his exceptional work championing cord blood research.

[University of Auckland] The Health Research Council of New Zealand has announced a total of $53.7 million in government funding for research into pressing health issues, including a trial to help New Zealanders quit vaping and a project to research Māori views on assisted dying.